{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/TELO/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-19T09:02:01.928Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":11308,"canonical_name":"Telomir Pharmaceuticals, Inc.","cik":"0001971532","uei":null,"lei":null,"duns":null,"ticker":"TELO"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":17,"clinical":1},"count":18,"timeline":[{"ts":"2026-10-06","kind":"sec.filing","form_type":"8-K","title":"8-K — Telomir Pharmaceuticals, Inc. — 2026-10-06","url_slug":"/sec/cik-0001971532/8-k/0001493152-26-045860","accession_number":"0001493152-26-045860","importance":35},{"ts":"2026-09-17","kind":"sec.filing","form_type":"8-K","title":"8-K — Telomir Pharmaceuticals, Inc. — 2026-09-17","url_slug":"/sec/cik-0001971532/8-k/0001493152-26-043053","accession_number":"0001493152-26-043053","importance":35},{"ts":"2026-09-16","kind":"sec.filing","form_type":"8-K","title":"8-K — Telomir Pharmaceuticals, Inc. — 2026-09-16","url_slug":"/sec/cik-0001971532/8-k/0001493152-26-042926","accession_number":"0001493152-26-042926","importance":35},{"ts":"2026-09-14","kind":"sec.filing","form_type":"8-K","title":"8-K — Telomir Pharmaceuticals, Inc. — 2026-09-14","url_slug":"/sec/cik-0001971532/8-k/0001493152-26-042483","accession_number":"0001493152-26-042483","importance":35},{"ts":"2026-08-19","kind":"sec.filing","form_type":"DEFA14A","title":"DEFA14A — Telomir Pharmaceuticals, Inc. — 2026-08-19","url_slug":"/sec/cik-0001971532/defa14a/0001493152-26-039116","accession_number":"0001493152-26-039116","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Telomir Pharmaceuticals, Inc. — 2026-08-14","url_slug":"/sec/cik-0001971532/schedule-13g-a/0001104659-26-097283","accession_number":"0001104659-26-097283","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Telomir Pharmaceuticals, Inc. — 2026-08-13","url_slug":"/sec/cik-0001971532/10-q/0001493152-26-037854","accession_number":"0001493152-26-037854","importance":45},{"ts":"2026-08-10","kind":"sec.filing","form_type":"8-K","title":"8-K — Telomir Pharmaceuticals, Inc. — 2026-08-10","url_slug":"/sec/cik-0001971532/8-k/0001493152-26-036742","accession_number":"0001493152-26-036742","importance":35},{"ts":"2026-07-28","kind":"sec.filing","form_type":"DEF 14A","title":"DEF 14A — Telomir Pharmaceuticals, Inc. — 2026-07-28","url_slug":"/sec/cik-0001971532/def-14a/0001493152-26-035026","accession_number":"0001493152-26-035026","importance":40},{"ts":"2026-07-27","kind":"sec.filing","form_type":"4","title":"4 — Telomir Pharmaceuticals, Inc. — 2026-07-27","url_slug":"/sec/cik-0001971532/4/0001493152-26-034811","accession_number":"0001493152-26-034811","importance":30},{"ts":"2026-07-27","kind":"sec.filing","form_type":"4","title":"4 — Telomir Pharmaceuticals, Inc. — 2026-07-27","url_slug":"/sec/cik-0001971532/4/0001493152-26-034812","accession_number":"0001493152-26-034812","importance":30},{"ts":"2026-07-27","kind":"sec.filing","form_type":"4","title":"4 — Telomir Pharmaceuticals, Inc. — 2026-07-27","url_slug":"/sec/cik-0001971532/4/0001493152-26-034813","accession_number":"0001493152-26-034813","importance":30},{"ts":"2026-06-15","kind":"sec.filing","form_type":"8-K","title":"8-K — Telomir Pharmaceuticals, Inc. — 2026-06-15","url_slug":"/sec/cik-0001971532/8-k/0001493152-26-028614","accession_number":"0001493152-26-028614","importance":35},{"ts":"2026-06-09","kind":"sec.filing","form_type":"3","title":"3 — Telomir Pharmaceuticals, Inc. — 2026-06-09","url_slug":"/sec/cik-0001971532/3/0001493152-26-027958","accession_number":"0001493152-26-027958","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"8-K","title":"8-K — Telomir Pharmaceuticals, Inc. — 2026-06-08","url_slug":"/sec/cik-0001971532/8-k/0001493152-26-027752","accession_number":"0001493152-26-027752","importance":35},{"ts":"2026-05-20","kind":"sec.filing","form_type":"8-K","title":"8-K — Telomir Pharmaceuticals, Inc. — 2026-05-20","url_slug":"/sec/cik-0001971532/8-k/0001493152-26-024517","accession_number":"0001493152-26-024517","importance":35},{"ts":"2026-05-14","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Telomir Pharmaceuticals, Inc. — 2026-05-14","url_slug":"/sec/cik-0001971532/10-q/0001493152-26-023010","accession_number":"0001493152-26-023010","importance":45},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"Telomir Pharmaceuticals, Inc.","title":"Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)","security_title":"PHASE1,PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07581314","excerpt":"[\"Triple-Negative Breast Cancer (TNBC)\",\"Advanced Triple-Negative Breast Cancer\",\"Metastatic Triple-negative Breast Cancer\"]","importance":45}]}